Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China
{{output}}
Background: The cost-effectiveness of tislelizumab plus chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC) was uncleared yet. The current analysis aimed to evaluate the cost-effective of adding tislel... ...
